Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 1, 1998, Pages 29-38

  Kowala, Mark C ^a   Valentine, Maria ^a   Recce, Ron ^a   Beyer, Sophie ^a   Goller, Nancy ^a   Durham, Stephen ^a   Aberg, Gunnar ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

ACE; Atherosclerosis; Captopril; HMG CoA reductase; Pravastatin

Indexed keywords

CAPTOPRIL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MESSENGER RNA; PRAVASTATIN; TRIACYLGLYCEROL;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; BLOOD PRESSURE; CELL COUNT; CELL SIZE; CONTROLLED STUDY; DRUG POTENTIATION; FOAM CELL; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MACROPHAGE; MALE; MICROSCOPY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SYRIAN HAMSTER;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; BLOOD PRESSURE; CAPTOPRIL; CHOLESTEROL; CRICETINAE; IMMUNOHISTOCHEMISTRY; LIPIDS; LIPOPROTEINS; MALE; MESOCRICETUS; PEPTIDYL-DIPEPTIDASE A; PRAVASTATIN; RNA, MESSENGER;

EID: 0031799430     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199807000-00005     Document Type: Article

References (60)

1. Grundy SM. HMG CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-33.
2. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hempil L. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40.
3. Blankenhorn DH, Azen SP, Kramsch DM, et al. and the MARS research group. The monitored atherosclerosis regression study (MARS): coronary angiographic changes with lovastatin. Ann Intern Med 1993;119:969-76.
4. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention trial. Circulation 1994;89:959-69.
5. Jukema JW, Albert VG, Bruschke AV, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderate elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
6. Furberg CD, Pitt B, Byington RP, Park J-S, McGovern ME. Reduction in coronary events during treatment with pravastatin. Am J Cardiol 1995;76:60-3c.
7. Kjekshus J, Pedersen TR. Reducing the risks of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995;76:64-8c.
8. Shepard J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
9. Pfeffer MA, Brawnwald E, Moye L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
10. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
11. La Ville AE, Seddon AM, Shaikh M, Rowles PM, Woolf N, Lewis B. Primary prevention of atherosclerosis by lovastatin in a genetically hyperlipidemic rabbit strain. Atherosclerosis 1989;78: 205-10.
12. Khachadurian AK, Shimamura T, Rozovski SJ, et al. Pravastatin decreases serum lipids and vascular cholesterol deposition in Watanabe Heritable Hyperlipidemic (WHHL) rabbits. Jpn Heart J 1991;32:675-85.
13. Hadjiisky P, Hermier D, Truffert J, De Gennes J-L, Grosgogeat Y. Effect of pravastatin, an HMG CoA reductase inhibitor, on blood lipids and aortic lipidosis in cholesterol-fed white Carneau pigeons. Biochim Biophys Acta 1993;1181:279-86.
14. Bocan TMA, Mazur MJ, Bak Mueller S, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis 1994;111:127-42.
15. Shiomi M, Ito T, Tsukada T, et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 1995;15:1938-44.
16. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-31.
17. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990;15(suppl 5):S65-72.
18. Charpoit P, Rolland PH, Friggi A, et al. ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries. Arterioscler Thromb 1993;13:1125-38.
19. Kowala MC. Captopril decreases accelerated atherosclerosis in hypertensive one kidney one clip rats fed cholesterol. Drug Dev Res 1993;29:100-7.
20. Jacobsson LS, Persson K, Aberg G, Andersson RGG, Karlberg BE, Olsson AG. Antiatherosclerotic effects of the angiotensin-converting enzyme inhibitors captopril and fosinopril in hypercholesterolemic minipigs. J Cardiovasc Pharmacol 1994;24:670-7.
21. Kowala MC, Recce R, Beyer S, Aberg G. Regression of early atherosclerosis in hyperlipidemic hamsters by fosinopril and captopril. J Cardiovasc Pharmacol 1995;25:179-86.
22. Fennessy PA, Campbell JH, Campbell GR. Perindopril inhibits both the development of atherosclerosis in cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. Atherosclerosis 1994;106:29-41.
23. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 1993;91: 1453-8.
24. Kowala MC, Grove RI, Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters: fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 1994;108:61-72.
25. Aberg G, Kowala MC, Molloy CJ. ACE inhibitors and atherosclerosis. In: Schachter M, ed. ACE inhibitors: current use and future prospects. London: Martin Dunitz, 1995:95-218.
26. Joris I, Zand T, Nunnari JJ, Krolikowski FJ, Majno G. Studies on the pathogenesis of atherosclerosis: I. adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats. Am J Pathol 1983;113:341-58.
27. Spady DK, Dietschy JM. Dietary saturated tnacylglycerols suppress hepatic low density lipoprotein receptor activity in the hamster. Proc Natl Acad Sci U S A 1985;82:4526-30.
28. Nicolosi RJ, Stucchi AF, Kowala MC, Hennessy LK, Hegsted DM, Schaefer EJ. Effect of dietary fat saturation and cholesterol on LDL composition and metabolism: in vivo studies of receptor and non-receptor-mediated catabolism of LDL in Cebus monkeys. Arteriosclerosis 1990;10:119-28.
29. Hirano T, Komuro F, Furukawa S, Nagano S, Takahashi T. Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis. Metabolism 1990;39:605-9.
30. Shiomi M, Ito T. Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watananbe heritable hyperlipidemic rabbits. Metabolism 1994;43:559-64.
31. Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 1992;41: 487-93.
32. Kowala MC, Nunnari JJ, Durham SK, Nicolosi RJ. Doxazosin and cholestyramine similarly decrease fatty streak formation in the aortic arch of hyperlipidemic hamsters. Atherosclerosis 1991;91: 35-49.
33. Ferrer P, Aberg G. Progression of atherosclerosis in cholesterol-fed cynomolgus monkeys during treatment with nifedipine. FASEB J 1990;4:A1151.
34. Keidar S, Kaplan M, Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cholesterol accumulation. Arterioscler Thromb Vasc Biol 1996;16: 97-105.
35. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to aortic endothelial cells. Clin Res 1994;42:15A.
36. Goetzl EJ, Klickstein LB, Watt KWK, Wintroub BU. The preferential human monocyte chemotactic activity of the substituent tetrapeptides of angiotensin II. Biochem Biophys Res Commun 1980;97:1097-1102.
37. Weinstock JV, Blum AM. Isolated liver granulomas of murine Schistosoma mansoni contain components of the angiotensin system. J Immunol 1983;131:2529-32.
38. Sugano M, Makino N, Tanaga T. The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits. Atherosclerosis 1996;127:123-9.
39. Erdos EG. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990;15(suppl 6):S20-4.
40. Wiemer G, Scholkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autocoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991;18:558-63.
41. Bath PM, Hassall DG, Gladwin AM, Palmer RM, Martin JF. Nitric oxide and prostacyclin: divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb 1991;11:254-60.
42. Cooke JP, Singer AH, Tsao P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992;90:1168-72.
43. Kowala MC, Mazzucco CE, Hartl KS, et al. Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters. Octimibate and BMY 42393 suppress monocyte chemotaxis, macrophage cholesteryl ester accumulation, scavenger receptor activity and tumor necrosis factor production. Arterioscler Thromb 1993;13:435-44.
44. Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE, McMurray J. Antioxidant effects of angiotensin converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl containing ACE inhibitors. J Cardiovasc Pharmacol 1992;19:330-40.
45. Parker RA, Sabrah T, Cap M, Gill BT. Relation of vascular oxidative stress, α-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters. Arterioscler Thromb Vasc Biol 1995; 15:349-58.
46. Kowala MC, Rose P, Stein PD, et al. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 1995;146:819-26.
47. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
48. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms: oxidation, inflammation and genetics. Circulation 1995;91:2488-96.
49. Whittington-Coleman PJ, Carrier O Jr, Douglas BH. The effects of propranolol on cholesterol-induced atheromatous lesions. Atherosclerosis 1973;18:337-45.
50. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest 1981;68:1366-9.
51. Hollander W, Kramsch DM, Franzblau C, Paddock J, Colombo MA. Suppression of atheroniatous fibrous plaque formation by anti-proliferative and anti-inflammatory drugs. Circ Res 1974; 34-5(suppl I):I131-41.
52. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci U S A 1987;84:5928-31.
53. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit LDL degradation in macrophages and slow the progression of atherosclerosis in the WHHL rabbit. Proc Natl Acad Sci U S A 1987;84: 7725-9.
54. Ryan US, Ryan JW, Whitaker C, Chiu A. Localization of angiotensin converting enzyme (kininase II). II. Immunocytochemistry and immunofluorescence. Tissue Cell 1976;8:125-45.
55. Caldwell PRB, Seegal BC, Hsu KC, Das M, Sofer RL. Angiotensin-converting enzyme: vascular endothelial localization. Science 1976;191:1050-1.
56. Sibony M, Gasc JM, Soubrier F, Alhenc-Gelas F, Corvol P. Gene expression and tissue localization of the two isoforms of angiotensin I converting enzyme. Hypertension 1993;21:827-35.
57. Bader M, Wagner J, Lee M, Ganten D. The role of the renin-angiotensin system in cardiovascular disease. Hypertens Res 1994; 17:1-16.
58. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996;94:2756-67.
59. Mitani H, Bandoh T, Kimura M, Totsuka T, Hayashi S. Increased activity of vascular ACE related to atherosclerotic lesions in hyperlipidemic rabbits. Am J Physiol 1996;271:H1065-71.
60. Hoshida S, Nishida M, Yamashita N, et al. Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril. Atherosclerosis 1997;130:53-9.